8th INT'L BIO FORUM & BIO EXPO JAPAN: ES Cell/iPS Cell to Tissue Engineering
* Reuters is not responsible for the content in this press release.
-What is the Future Potential?-
TOKYO--(Business Wire)--
It is still fresh in our minds the day President Obama lifted an eight-year-old
ban on embryonic stem cell research, signing an executive order, calling it as
"an important step in advancing the cause of science in America."
As the research for ES cell (embryo-stem cell) is making its way to practical
use along with iPS cell (induced pluripotent stem cell), Asia`s largest Bio
Event, INT`L BIO FORUM & BIO EXPO JAPAN will be held at Tokyo from July
1(Wed)-3(Fri), delivering up-to-date information and technologies on the above
topics and related issues at the conference hall. Various companies with
leading-edge technologies will be present as well at the exhibition area, making
this event an indispensable one for coverage.
SPECIAL SESSION 7 [INT`L BIO FORUM & BIO EXPO JAPAN]
July 3, Fri. 10:30-12:00
ES/iPS Cells and its Potential
--Future Applications to Tissue-engineering and Drug Discovery--
Dr. Jane S. Lebkowski of Geron Corp., the world`s first doctor to make ES cell from human, and Dr. Nakatsuji, famous for establishing ES cell in Japan, of Kyoto University, will deliver speeches on the potential of ES/iPS cell and future applications to tissue-engineering and drug discovery.
Dr. Norio Nakatsuji Dr. Jane S. Lebkowski
Director, Institute for Integrated Senior Vice President & Chief
Cell-Material Sciences, Scientific Officer,
Kyoto University Geron Corp.
SPECIAL SESSION 3 [INT`L BIO FORUM & BIO EXPO JAPAN]
July 2, Thur. 10:30-12:00
Outstanding Progress in Tissue-engineering and Caner Treatment
--Nano Bio Research Leading Way to Future Treatment--
Two Japanese professors from Tohoku University and Tokyo Women`s Medical University will be making speeches on the development of tissue-engineering and cancer treatment, also referring to its challenges and progresses.
Dr. Noriaki Ohuchi Dr. Teruo Okano
Professor and Chairman, Div. of Professor and Director, Institute of
Surgical Oncology, Advanced Biomedical Engineering
Graduate School of Medicine, and Science,
Tohoku University Tokyo Women's Medical University
BIO ACADEMIC FORUM [INT`L BIO FORUM & BIO EXPO JAPAN]
Bio Academic Forum is held inside the exhibition area, where 168 presenters from universities and national institutes present their latest research on bio technologies. Below are some of the presenters who will present about iPS cell/ES cell/tissue engineering.
-Regulation of stem cells and the application for avian biotechnology July 2, Thur. 11:30-12:00
Shinshu University, Professor Hiroshi Kagami
-Tissue Engineering for Corneal Blindness July 2, Thur. 10:50-11:20
Doshisha University, Associate Professor Noriko Koizumi
-Adipose-derived stem cells for tissue repair and regeneration July 3, Fri. 15:50-16:20
Nippon Medical School, Associate Professor Hiroshi Mizuno
EXHIBITION VENUE [INT`L BIO FORUM & BIO EXPO JAPAN]
New Drug Discovery Screening System from Japanese Technology
ASONE CORPORATION
Asone Corporation will exhibit various systems including `ASONECell Picking system` which develops applications utilizing ES Cell and iPS Cell.
Laser Enabling High Throughput Analysis and Processing!
CYNTELLECT INC./ SUMMIT PHARMACEUTICALS INT`L
This company will bring unique cell processing system capable of accelerating iPS and Stem Cell research which improves cell purification, in addition to software and kit customized for cell secretion detection.
Partnering Opportunities of LICENSING iPS CELL PATENTS!
iPS ACADEMIA JAPAN, INC.
As patent of making iPS Cell (established by Dr. Yamanaka of Kyoto University) was enacted last September, iPS ACADEMIA JAPAN will be at the booth to discuss the possibilities of partnership of licensing iPS cell patents.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5981805&lang=en
INT`L BIO FORUM & BIO EXPO JAPAN Show Management
Reed Exhibitions Japan Ltd.
Kayo Nomura, +81-3-3349-8509
nomurak@reedexpo.co.jp
Fax: +81-3-3349-4922
Copyright Business Wire 2009
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.



Follow Reuters